Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin C (MMC) administered weekly into the bladder for 5 weeks [clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913]

Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin C (MMC) administered weekly into the bladder for 5 weeks [clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913]

Sponsor's website
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913
A Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Superficial Bladder Cancer [clinicaltrials:NCT00318643]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin C (MMC) administered weekly into the bladder for 5 weeks [clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913]

Sponsor's website
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913
Bio2RDF identifier
78f6f53504fdbfc97f9118071980d913
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913
measure [clinicaltrials_vocabulary:measure]
Determine the maximum tolerate ...... y into the bladder for 5 weeks
description
identifier
clinicaltrials_resource:78f6f53504fdbfc97f9118071980d913
title
Determine the maximum tolerate ...... y into the bladder for 5 weeks
@en
inDataset
type
label
Determine the maximum tolerate ...... 6f53504fdbfc97f9118071980d913]
@en